At this 12 months’s ASCRS assembly in Boston, Massachusetts, we caught up with Nir Shoham-Hazon, MD. He is the director of the Miramichi EyeNB Centre of Excellence in New Brunswick, Canada. In dialog with Ophthalmology Times Europe, Dr Shoham-Hazon offered highlights from his two paper displays.
Editor’s notice: The under transcript has been frivolously edited for readability.
Hello, my identify is Nir Shoham-Hazon. I’m a glaucoma and superior anterior section surgeon, director of the Miramichi EyeNB Centre of Excellence, from Miramichi, New Brunswick, Canada. We’re right here in Boston for ASCRS, the place I offered two papers on behalf of the iTrack microcatheter from Nova Eye. My first paper handled remedy burden of sufferers with main open angle glaucoma, which can be on 3+ drugs. What we noticed over 12 months was that sufferers, at baseline, IOPs had been 20, and on the 12-month follow-up, IOPs had been within the mid-teens. When we take a look at the remedy burden, so most sufferers had been on 3.5 remedy courses, and on the finish of the follow-up had been at 2.5 drugs.
In phrases of our glaucoma severity, most sufferers had been having delicate illness. When we additionally take a look at the protection and efficacy of the process, there was a big discount within the remedy burden to 2.5 mitigation courses. Some sufferers had been on oral carbonic anhydrase preoperatively, and had been off it within the submit, final comply with up at 12 months. There was one affected person that had a transient hyphema, and since this was a really distinctive group of sufferers, two sufferers, which was about 1%, did require additional filtration surgical procedure. Overall the protection and efficacy of the iTrack microcatheter from Nova Eye did show itself on this very distinctive affected person group.
The second paper that I offered was on the protection and efficacy of the iTrack microcatheter from Nova Eye, dealing in sufferers with main angle closure glaucoma. This was a novel paper, taking a look at 47 eyes, wanting on the security and efficacy of a blended process in main angle closure sufferers. Traditionally, main angle closure glaucoma was handled with a laser peripheral iridotomy, adopted by filtration surgical procedure if IOPs weren’t managed. We now have a minimally invasive glaucoma process that’s each protected and efficacious in coping with main angle closure glaucoma. Forty-seven sufferers in our cohort both went by way of an iTrack canaloplasty Ab-interno as a standalone process or mixed with cataract surgical procedure.
What we noticed in the complete group is that IOP preoperatively had been round 20 millimeters of mercury, and within the post-op mixed group, round mid-teens. However, once we divided the teams into managed and uncontrolled, we did see that the uncontrolled group really had a baseline IOP of 25 leading to a post-op interval of IOP of decrease teenagers, so round 12. There was a big discount in remedy burden on these eyes. One case of transient hyphema. In conclusion canaloplasty Ab-interno with the iTrack microcatheter by Nova Eye was protected and efficacious in sufferers requiring cataract and glaucoma process.
[adinserter block=”4″]
Source link
